07:00 , Jul 23, 2012 |  BioCentury  |  Product Development

Debio's dual deal

Debiopharm Group has been stocking up its early stage cancer pipeline with assets it believes have best-in-class potential, the latest being a preclinical dual tyrosine kinase inhibitor from Ascepion Pharmaceuticals Inc. The deal is the...